Cancer Cell Paper Identifies "Avidity Enhancement" As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia - Seite 2

The z-Movi Cell Avidity Analyzer measures cell avidity, or level of binding, between immune cells and their targets, enabling researchers to identify the most potent immunotherapeutic effector cells. This unique technology provides predictive, reproducible, and fast results at single-cell resolution. LUMICKS' cell avidity solutions use acoustics to measure forces and interactions between cells, with the goal of shortening the drug development cycle of immunotherapies and reducing failure rates in clinical trials. First introduced in 2020, the z-Movi is being rapidly adopted by academic and biopharma laboratories around the world.

About the Study Findings.

Unlike other forms of leukemia, AML has been notoriously difficult to successfully target using CAR T cells. Researchers believe this is due to both low expression of the antigenic targeted protein on the cancer cells and unstable expression of activating receptors on the T cells.

In this publication, the researchers have shown that increasing avidity of the CAR T cells to their target cells leads to enhanced tumor killing in vitro as in mouse models. Target protein expression on the cancer cells was chemically enhanced using available therapeutics and/or changing the design of the CAR to stabilize its expression on the T cells. Through this method, the researchers show that enhancing cell avidity for therapeutic efficacy can be achieved by modulating the tumor cell or modulating the surface of the T cell. Either strategy increased the sensitivity of the tumor to CAR T mediated clearance, confirming cell avidity as a crucial biomarker in immune oncology.

About LUMICKS

LUMICKS is a leading life science tools company that develops equipment for Dynamic Single-Molecule and Cell Avidity analysis, two rapidly emerging areas in biology research and immuno-oncology. LUMICKS' tools allow researchers to build the crucial and yet unfinished bridge between structure and function at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms. LUMICKS' C-Trap Optical Tweezers – Fluorescence & Label-free Microscopy, allows scientists to analyze complex biological processes in real-time. Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

For more information contact:

Dr Paul Wheeler, Chief Commercial Officer, media contact
[e-mail]

Andre Nel, Chief Financial Officer, investor contact
[e-mail]